Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Neuromuscular

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 33.3%Moderate 3 · 50%High 1 · 16.7%

Change in disability after 4 weeks disability grade change. Scale from: 0 to 10. · patients with Guillain‐Barré syndrome

1 finding from 1 review

Intravenous immunoglobulin for Guillain‐Barré syndrome 2014 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 536 participants
Moderate

Number improved by 1 or more disability grades after 4 weeks · patients with Guillain‐Barré syndrome

IVIg showed no clear difference in number improved by 1 or more disability grades after 4 weeks compared with PE (moderate certainty).

1 finding from 1 review

Intravenous immunoglobulin for Guillain‐Barré syndrome 2014 · Cochrane Headline outcomes only
RR 1.08 [0.94, 1.23]
6 studies · 567 participants
Moderate

Dead or disabled after 12 months (48 weeks) · patients with Guillain‐Barré syndrome

IVIg showed no clear difference in dead or disabled after 12 months (48 weeks) compared with PE (low certainty).

1 finding from 1 review

Intravenous immunoglobulin for Guillain‐Barré syndrome 2014 · Cochrane Headline outcomes only
RR 0.98 [0.55, 1.72]
1 study · 243 participants
Low

Relapse or treatment‐related fluctuation · patients with Guillain‐Barré syndrome

IVIg showed no clear difference in relapse or treatment‐related fluctuation compared with PE (low certainty).

1 finding from 1 review

Intravenous immunoglobulin for Guillain‐Barré syndrome 2014 · Cochrane Headline outcomes only
RR 0.89 [0.42, 1.89]
3 studies · 445 participants
Low

Patients in whom treatment was discontinued · patients with Guillain‐Barré syndrome

IVIg leads to lower participants in whom treatment was discontinued compared with PE (high certainty).

1 finding from 1 review

Intravenous immunoglobulin for Guillain‐Barré syndrome 2014 · Cochrane Headline outcomes only
RR 0.14 [0.05, 0.36]
4 studies · 498 participants
High

Number of patients with adverse events attributed to treatment · patients with Guillain‐Barré syndrome

IVIg showed no clear difference in number of participants with adverse events attributed to treatment compared with PE (moderate certainty).

1 finding from 1 review

Intravenous immunoglobulin for Guillain‐Barré syndrome 2014 · Cochrane Headline outcomes only
RR 0.84 [0.54, 1.3]
4 studies · 388 participants
Moderate